Most Recent Articles by Noah Pines
A relative's illness challenges a pharma consultant's view of industry progress.
With some of the biggest patent expiries due to pass in 2013, the next two years will be important in terms of pharma's return to growth, says Sanford Bernstein's Dr. Tim Anderson in a discussion with Noah Pines
Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.
The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding.
Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.
More Articles by Noah Pines
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Novartis aims to bring first oral asthma drug to market in two decades
- What five different pharma marketing careers look like
- Veeva and QuintilesIMS tussle over customer reference data
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media